Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.
Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder PJ, Ellenberg SS, Travison TG, Brock GB, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Antonic KG, Tenover JL, Tan HM, Ho Chee Kong C, Tan WS, Marks LS, Ross RJ, Schwartz RS, Manson P, Roberts SA, Skovsager Andersen M, Velling Magnussen L, Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhillo WS, Bhattacharya S, Brazzelli M, Jayasena CN.
Hudson J, et al.
Lancet Healthy Longev. 2023 Oct;4(10):e561-e572. doi: 10.1016/S2666-7568(23)00169-1.
Lancet Healthy Longev. 2023.
PMID: 37804846
Free article.
We aimed to evaluate whether subgroups of men with low testosterone derive any symptomatic benefit from testosterone treatment. ...However, due to more severe baseline symptoms, the absolute level of sexual function reached during testosteron …
We aimed to evaluate whether subgroups of men with low testosterone derive any symptomatic benefit from testosterone …